Abstract 201P
Background
Despite advances in breast cancer (BC) treatment, current therapies often fail in metastatic settings, underscoring the need for innovative strategies. Neutrophils, known for their dual role in cancer, emerged as potential therapeutic targets. Circulating neutrophils are classified as high density neutrophils (HDN) which are pro-inflammatory and cytotoxic, and low density neutrophils (LDN), which promote tumor growth and metastasis, mirroring their tumor counterparts. Our group found significant LDN accumulation in patients’ blood, correlating with advanced disease and poor prognosis. To clarify the role of neutrophils in BC, we focused on LDN’ immunosuppressive function, namely their arginase activity, known to inhibit T cell antitumor response.
Methods
Both neutrophil populations were obtained from the blood of 146 BC patients by density gradient centrifugation and characterized by flow cytometry. We conducted in vitro assays and co-cultures with patient-derived cells to explore LDN-mediated immunosuppression.
Results
In 3D co-cultures, HDN showed strong cytotoxicity against BC cell lines, while LDN failed to induce tumor cell death. Conversely, LDN exhibited enhanced immunosuppressive traits, including elevated PD-L1 expression, which impairs T cell activation. In addition, T cells cultured in LDN-conditioned medium showed significant activation impairment, suggesting LDN-released soluble factors as mediators of this effect. This suppression was partially reversed by an arginase inhibitor. Although arginase levels were similar in LDN and HDN, we identified a specific LDN subset with heightened arginase activity, which displays other pro-tumor features, including higher PD-L1 and MMP-9 expression, and was linked with poorer prognosis in this BC cohort.
Conclusions
Our findings highlight the heterogeneity of neutrophils and the potential of identifying distinct immunosuppressive LDN subsets that contribute to tumor progression by impairing antitumor T cell responses. Our data advance the understanding of LDN in BC and highlight their potential as biomarkers for disease monitoring, predicting therapy responses, and as targets for novel immunotherapies.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
Resources:
Abstract
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
Resources:
Abstract
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
Resources:
Abstract
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
Resources:
Abstract
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
Resources:
Abstract
114P - Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS=5: Updated results from a real-world study
Presenter: Qi Xu
Session: Poster Display session
Resources:
Abstract
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
Resources:
Abstract
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
Resources:
Abstract
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
Resources:
Abstract
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session
Resources:
Abstract